Surgeons (STS) are used to determine the surgical risk in patients undergoing transcatheter aortic valve implantation (TAVI). However, it is knon that these risk scores have been developed to predict peri-operative surgical mortality. There is no a specific risk score to determine peri-procedural mortality in patients undergoing TAVI and therefore novel risk scores are required for predicting peri-procedural and long term mortality in these patients. In this tudy, we found that all conventional risk scoring systems overestimated in-hospital mortality. However, we demonstrated that male gender and low albumin level before the procedure were independent predictors of long term mortality in patients undergoing TAVI.
INTRODUCTION
Aortic stenosis (AS) is the most frequently diagnosed valvular disease worldwide [1, 2] .
Severe symptomatic AS has a poor prognosis with conservative treatment [3] . Leaving the patients untreated results in the emergence of symptoms and a high rate of mortality: approximately 30-50% of the patients die in the first 2 years after symptoms became manifest [4] [5] [6] . Because AS is an old-age disease, comorbid situations are usually more frequent in these patients. This situation also makes surgery difficult. It has been reported that 30% of severely symptomatic patients are inoperable in clinical practice because of multiple clinical comorbidities [7, 8] .
Transcatheter aortic valve implantation (TAVI) is a well-established alternative to surgical valve replacement in patients at high surgical risk [9] . Surgical risk is determined by conventional surgical risk scoring systems. These risk scores including the European System for Cardiac Operative Risk Evaluation II (EuroSCORE-II), Logistic EuroSCORE and the Society of Thoracic Surgeons (STS) risk scores, were developed to predict peri-operative mortality and morbidity in patients undergoing cardiac surgery [10] [11] [12] . Therefore it is not known whether these surgical risk scores can be used for predicting early and late-stage mortality for patients undergoing TAVI. In addition, the risk factors related with late-stage mortality for patients undergoing TAVI has not completely elucidated yet. Because of the insufficient predictive ability of these risk scores, the Valve Academic Research Consortium (VARC)-2 consensus document stated that other anatomical and biological tools are needed for the evaluation of risk and outcome of patients undergoing TAVI [13] . Since then, new predictors and risk scores were developed to predict the risk of TAVI. Recent studies have demonstrated that male gender and hypoalbuminemia, as predictor of frailty, are the independent predictors of mortality in patients undergoing TAVI [14, 15] .
The aim of our study is to evaluate the predictive value of conventional risk scores for predicting long-term mortality in the patients undergoing TAVI. Also, the risk factors that do not exist in the scoring systems but might be effective as a predictor of long-term mortality will be assessed.
METHODS

Patient Selection
A total of 121 patients who underwent transfemoral TAVI between June 2012 and March 2016 were included in this study. 119 patients had severe calcific AS and 2 patients had symptomatic severe aortic regurgitation. All procedures were conducted by the same experienced team. A cardiac team evaluated all the patients, and the decision on TAVI was made as stated in the current guidelines [10] . The echocardiographic criteria of severe AS were determined as follows: aortic valve area (AVA) < 1.0 cm 2 , and/or mean transvalvular gradient > 40 mmHg, and/or maximal transvalvular blood flow velocity > 4.0 m/sec. Lowflow, low-gradient aortic stenosis was defined as AVA < 1 cm 2 , mean gradient < 40 mmHg, ejection fraction (EF) < 50%, stroke volume index (SVi) ≤ 35 mL/m 2 . Paradoxical low-flow, low-gradient aortic stenosis was defined as AVA < 1 cm 2 , mean gradient < 40 mmHg, EF ≥ 50%, SVi ≤ 35 mL/m 2 [16] . The study was approved by the Ethics Committee of Dokuz Eylul University.
Imaging procedures
All patients were evaluated by transthoracic echocardiography (Philips HD11XE, SONOS 4500). Echocardiographic measurements were obtained according to the Journal of the American Society of Echocardiography guideline. We used transesophageal echocardiography and/or computed tomography to evaluate aortic valve structure, degree of calcification and stenosis, and aortic valve area, annulus and ascending aorta. Aortic annulus was measured from hinge point to hinge point. Coronary angiography procedures were performed for all patients before TAVI procedure. Patients requiring revascularization were treated before TAVI.
Study plan
The baseline characteristics of all patients, the mortality and morbidity rates during the procedure and the long-term follow-up were reviewed retrospectively. Complications were evaluated according to VARC-2 criteria. The echocardiography and laboratory test of all patients were obtained before the procedure, 24 hours after the procedure, and before the hospital discharge. All patients were evaluated at the outpatient clinic in the 1st, 3rd, 6th, 12th, 24th, and 36th months for follow-up after the procedure.
Transcatheter aortic valve implantation procedure
The TAVI procedures were performed in the catheter laboratory under general anesthesia or The peripheral entry site was then closed and angiographic control was performed.
Post-procedural follow-up
Dual antiaggregant therapy for 6 months, consisting of aspirin and clopidogrel, was prescribed to the patients. Single or dual (based on the risk of bleeding) antiaggregant therapy in combination with oral anticoagulants (OAC) for at least 3 months was given to patients who had to receive OAC due to any reason. After the general condition of the patients became stable, they were discharged from the hospital, scheduling the follow-up visits in the 1st month, 3rd month, 6th month, and the 1st year. In the follow-up visits, the functional capacities of the patients and the findings from their routine physical examinations, echocardiograms, and laboratory tests were evaluated. Survival data of the patients were obtained via the joint recording system of our hospital and the ministry of health and/or by contacting the patients by phone.
Statistical Analysis
Statistical analyses were performed with Statistical Package for Social Sciences 15.0.
Kolmogorov-Smirnov test was performed to evaluate whether the data conformed to a normal distribution. Continuous variables were presented as mean (SD) and/or median interquartile range), and compared with Student's T-test and/or Mann-Whitney U test according to the distribution. Categorical variables were presented as number and percentages. Chi-square test and Fisher's exact test were performed for the comparisons of categorical variables. Preprocedural and postprocedural variables were compared with the paired t-test. Kaplan-Meier survival curve was used for determining the survival rates and estimated life expectancy; the log-rank test was used for the comparison. Multivariate logistic regression analysis was performed to determine the independent predictors of long-term mortality. Receiver operating characteristic (ROC) curve analysis was performed for determining the best predictive value in the prediction of mortality. A P-value of < 0.05 was accepted to indicate statistically significance.
RESULTS
A total of 121 patients were included in this study. The mean age of the patients were 78 (7.7) years. The baseline characteristics of the patients are presented in Table 1 Maximum (P = 0.01) and mean transaortic gradients (P = 0.02) decreased, while AVA (P < 0.001) and EF (P < 0.001) increased significantly after the procedure. In addition, creatine level increased significantly on the first day after the procedure when compared to the pre-procedural status (P < 0.001). When > 25% increase in post-procedural creatine values was considered as a significant creatine increase, a significant creatine increase was observed in 29 (24.2%) patients (Table 3) .
Complication rates are listed in Table 4 . Peri-procedural death was not developed in any patient, while in-hospital mortality was developed in 2 (1.7%) patients. Mean duration of follow-up was 23.2 months. One patient was lost to follow-up. All cause mortality was observed in 26 patients during the follow up. 10 deaths were associated with non-pneumonic sepsis, 5 deaths with pneumonia, 3 deaths with kidney failure, 1 death with trauma related hemorrhagic cerebrovascular accident, 2 deaths with cancer and 5 deaths with the worsening heart failure. According to the Kaplan-Meier survival data, 3-month survival rate was 93.3%, 6-month survival rate was 91.6%, 1-year survival rate was 85.9%, 2-year survival rate was 78.3%, and 3-year survival rate was 71.3% ( Figure 1A) .
The mean Logistic EuroSCORE, EuroSCORE-II and STS were 27.4 (9.7), 7.9 (4.6) and 4.6 (2.4), respectively. It was observed that none of these scores could estimate inhospital mortality (1.7%) accurately and the all of these risk methods overestimated the in hospital mortality. However, when the mortality rates corresponding to these scores were reviewed, it was found that the mortality risk estimation of the STS score corresponded to the mortality rate of approximately the 2nd month, the EuroSCORE-II to the mortality rate of the 6th month and the Logistic EuroSCORE to the mortality rate of the 30th month ( Table 5 ).
Gender and Death
Kaplan-Meier survival data according to the gender differences is shown in Figure 1B .
Survival rate was significantly higher in woman compared to man (P = 0.008).
Age and Death
The patients were divided into 3 groups for researching the effect of age on mortality: ≤ 75, 76-85 and ≥ 85. No significant difference was detected among groups in terms of survival (P = 0.99, Figure 1C ).
Determination of Predictors Affecting Long-Term Mortality
Multivariate logistic regression analysis demonstrated that male gender (OR: 5.668, 95% CI:
1.055-30.446, P = 0.04) and pre-procedural albumin level (OR: 0.109, 95% CI: 0.018-0.654, P = 0.02) were independent predictors of long-term mortality ( Table 6 ). ROC curve analysis showed that the 3.4 cut off value of albumin predicted mortality with a sensitivity of 73% and specificity of 65% (Figure 2 ).
DISCUSSION
In this study, we aimed to determine whether the traditional risk scores indeed had an effect on short-term and long-term survival in TAVI-applied patients. We also investigated the other potential mortality-related factors, which were not included in the risk scoring systems previously, in TAVI-applied patients. The main finding of our study was that any traditional risk scoring system did not accurately predict the short-term mortality in TAVI-applied patients and that these risk scores overestimated the in-hospital and short term mortality. In addition, we found that male gender and the low albumin levels before TAVI procedure were the independent predictors of mortality.
The early and long term mortality rates of TAVI-applied patients have been examined by several large-scale studies. The in-hospital and long-term mortality rates of our study were lower compared to these large-scale studies. The 30-day mortality rates were 5% in the PARTNER study cohort-B, 3.9% in the PARTNER 2 study, and 9.2% in the recently published FRANCE-2 study [15] [16] [17] [18] . However, the 30-day mortality rate according to the VARC-2 criteria was only 1.7% in our study population. Regarding the late mortality, the 1st
year mortality rate was 30.7% in the TAVI group of the PARTNER Cohort-B, 24.3% in the PARTNER Cohort-A, and 23.2% in FRANCE-2, but it was 14.1% in our study [15] [16] [17] [18] . The 2nd year mortality rate was 33.9% in the PARTNER Cohort-A and 32.9% in FRANCE-2, but it was 21.7% in our study [18, 19] . The low mortality rates in our study may be explained firstly by the conduct of the intervention by the same experienced heart team. Secondly, the patients in our study underwent TAVI in the period from 2012 to 2016, when the advanced technologies and new-generation valves were introduced.
The logistic EuroSCORE, EuroSCORE-II, and STS are the three scoring systems used for predicting peri-operative mortality and determining the risk of cardiac surgery [10] [11] [12] .
These scoring systems have recently been introduced for deciding whether the intervention will be surgical or percutaneous in patients whose aortic valves will be intervened. TAVI is applied to high-risk patients based on these scoring systems. Although it has been demonstrated that the higher risk scores is associated with poor outcomes [20] , it is known that these risk scores overestimate the procedural risk in TAVI [21] . The mean STS score and logistic EuroSCORE were 11.2 (5.8) and 26.4 (17.2) in PARTNER study cohort-B, but the 30-day mortality rate was only 5% [15] . The mean STS score was 5.8 (2.1) in the PARTNER-2 study, but 30-day mortality rate was only 3.9% [17] . In FRENCH-2 registry, the mean Logistic Euroscore was 21.8 (14.1) in balloon-expandable valve group and 21.5 (14.5) in selfexpandable valve group; however, 30-day mortality rate was 9.2% [18] . Similarly, in our study, none of the scores predicted the in-hospital mortality accurately in TAVI-applied patients. We demonstrated that the STS and EuroSCORE-II had a similar and realistic predicting power; however, the mortality predictions made by the logistic EuroSCORE were exaggerated. The closest to precise predictability for actual short-term mortality was observed with STS. The overestimated predictions obtained by these scoring systems in TAVI are not surprising since TAVI is an easier procedure compared to surgery. In our study, we investigated the use of these scoring systems in a different field in TAVI-applied patients:
which risk score estimates which month mortality? Our analyses of revealed that; STS score corresponded to the 2nd-month mortality rate, EuroSCORE-II corresponded to the 6th-month mortality rate and logistic EuroSCORE corresponded to the 30th-month mortality rate. We suggest that the current scoring systems can be used for a different purpose in TAVI-applied patients.
The overestimation of mortality by classical risk scoring systems has led to the development of new risk estimation scorings and the emergence of new predictive parameters for mortality in TAVI-applied patients [22] [23] [24] . We found that male gender and the preprocedural low albumin level were independent predictors of the long-term mortality after TAVI. Similar to our study, Sanino et al. [25] reported that the 1st-year mortality rate after TAVI in males was higher compared to females. Moreover, the data coming from large studies also reported that male patients had higher mortality after TAVI [25] [26] [27] . The higher frequency of previous history of myocardial infarction and the lower left ventricular EF in this subgroup of our study may explain this result.
Frailty, which is not included in the risk scoring systems, is one of the most significant risk factor for determining the surgical risk according to VARC-2 [28, 29] . However, the objective parameters of frailty are limited. One of the important parameters used in this field is albumin. The albumin level is expected to be low in frail patients due to a potential risk for irregular eating and/or malnutrition. The prognostic value of frailty to perform a risk assessment before TAVI was investigated in some studies [30] . However, the data on the prognostic value of albumin levels as a frailty marker is limited. In our study, it was demonstrated that low pre-procedural albumin level was independently predicted post-TAVI long-term mortality. Furthermore, each unit decrease in the pre-procedural albumin level increased the long term all cause mortality by 11%. This was found to be similar to the recently published data in the literature [14] . It can be concluded that mortality will be higher in patients undergoing TAVI which has low blood levels of albumin. Even though our study is important for demonstrating the clinical importance of the pre-procedural albumin level, we believe that further large-scale clinical studies are needed to confirm these results because of the small sample size of our study.
TAVI is commonly performed under general anesthesia with endotracheal intubation.
However, advances in transcatheter valve technology have made TAVI feasible with local anesthesia. Although general anesthesia has some advantages such as provide a safety environment for the operator and facilitating the use of devices during the procedure, recent studies have demonstrated that it is associated with higher 30-day mortality, longer procedure time and prolonged hospitalization [31] . In our study, the majority of patients had undergone TAVI with general anesthesia. Unfortunately, we did not record the anesthesia type and long term mortality was assessed without discrimination on these patients. Nevertheless, our 30-day mortality rate was quite lower (1.7%). In addition, we think that the type of anesthesia may not affect the long term mortality in TAVI. It could be better to determine the effect of anesthesia type on short and long term mortality in our study.
Study Limitations
The most important limitation of our study was the relatively small number of the patients and its single center nature. The heterogeneity as a result of using valves from different generations and different brands constitutes the other limitation of our study. Moreover, recent studies confirmed the superiority and non-inferiority of TAVI as compared to surgical aortic valve implantation in low risk patients. Therefore, our results cannot be generalized to the all population of patients who currently qualified for TAVI.
Conclusions
Although all conventional risk scoring systems overestimated in-hospital mortality, we found that STS predicted 2-month mortality, EuroSCORE-II predicted 6-month mortality and Logistic EuroSCORE predicted 30-month mortality. To our knowledge, this is the first study regarding this issue. In addition, pre-procedural low blood albumin level was found to be an independent predictor of long-term mortality in patients undergoing TAVI. This shows that malnutrition and frailty are an important parameter to be considered in this group of patients.
Therefore, we suggest that TAVI should be performed before the clinical deterioration and increased frailty. Peri-procedural death (%) 0 (0)
In-hospital mortality (%) 2 (1.7)
Abbreviations: VARC, valve academic research consortium; others, see Table 1 
